About UsThe VITATOPS Study is a multi-centres, double-blind, randomised, placebo-controlled trial of multi-vitamin therapy (2 mg folic acid, 25 mg B6 and 0.5 mg B12) in the secondary prevention of stroke and other vascular events (myocardial infarction and vascular death) among patients with previous stroke or TIA.
VITATOPS is funded by the National Health and Medical Research Council of Australia and the National Heart Foundation and has ethical approval in Australia, Austria, Belgium, Brazil, Hong Kong, India, Italy, Malaysia, Moldova, Netherlands, New Zealand, Pakistan, Philippines, Portugal, Republic of Georgia, Serbia & Monte Negro, Singapore, Sri Lanka, United Kingdom and United States of America.
The VITATOPS Study began in November 1998 and ended in December 2009. The trial randomised 8,164 patients worldwide from 123 medical centres in 20 countries on five continents. Randomisation ceased on 31 December 2008 and patient followed-up data was collected until 30 June 2009. The trial results will be presented on 26th May 2010 in Barcelona at the European Stroke Conference.